Study: GLP-1 weight-loss drugs might lower, not increase, teen suicide risk
In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and ...
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies ...
Not Many Employers Cover GLP-1 Weight Loss Drugs
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
LifeVantage Introduces the MindBody GLP-1 System™ Transforming Weight Management into a Sustainable Lifestyle
Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Benefits Pro5d
Balancing the costs of GLP-1 weight loss drug coverage: New CBO report has some answers
According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight ...
ahajournals.org3d
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, ...